NancyWPeacockMD

PubMed

• 6 citations
  A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).
  Denise A. Yardley, Robyn R. Young, Kerin B. Adelson, Andrea Silber, Jose E. Najera, Davey B. Daniel, N. W. Peacock, L Finney, Susan J. Hoekstra, Mythili Shastry, John ...> ;Clinical Breast Cancer. 2021 Oct 28
• 14 citations
  A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers
  Johanna C. Bendell, Ahmed Zakari, Evan Z. Lang, David M. Waterhouse, Douglas Flora, Kathryn B. Alguire, Michael McCleod, N. W. Peacock, Peter Ruehlman, Cassie M. Lane,...> ;Cancer Investigation. 2016 Apr 29
• 42 citations
  A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response ...
  Denise A. Yardley, N. W. Peacock, Mythili Shastry, Howard A. Burris, Rebecca Bechhold, C Hendricks, Carl N. Yoshizawa, Amy P. Sing, John D. Hainsworth> ;Breast Cancer Research and Treatment. 2015 Oct 27
• 19 citations
  Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase...
  Denise A. Yardley, Linda D. Bosserman, Joyce O'Shaughnessy, William N. Harwin, Susan Kay Morgan, Victor M. Priego, N. W. Peacock, J. David Bass, Howard A. Burris, John...> ;Breast Cancer Research and Treatment. 2015 Oct 12
• 14 citations
  Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer
  Denise A. Yardley, Dianna Shipley, N. W. Peacock, Mythili Shastry, Rajiv Midha, Victor M. Priego, John D. Hainsworth> ;Breast Cancer Research and Treatment. 2015 Jul 9
• 126 citations
  Antiemetic Guideline Consistency and Incidence of Chemotherapy-Induced Nausea and Vomiting in US Community Oncology Practice: INSPIRE Study
  James Gilmore, N. W. Peacock, Anna Gu, Stephen Szabo, Melissa Rammage, Joyce Sharpe, Sally Haislip, Toni S. Perry, Tim Lee Boozan, Katherine Meador, Xiting Cao, Thomas...> ;Journal of Oncology Practice. 2014 Jan 1
• 40 citations
  Patient perspectives on breast cancer treatment plan and summary documents in community oncology care
  Victoria S. Blinder, Virginia W. Norris, Nancy W. Peacock, Jennifer J. Griggs, David P. Harrington, Anne Moore, Richard L. Theriault, Ann H. Partridge> ;Cancer. 2013 Jan 1
• 35 citations
  Phase 1 Results From a Study of Romidepsin in Combination With Gemcitabine in Patients With Advanced Solid Tumors
  Suzanne F. Jones, Jeffrey R. Infante, David R. Spigel, N. W. Peacock, Dana S. Thompson, F. Anthony Greco, William McCulloch, Howard A. Burris> ;Cancer Investigation. 2012 May 31
• Patient perspectives on a treatment plan and summary program in community oncology care.
  Blinder VS, Norris VW, Peacock NW, Griggs JJ, Harrington DP, Moore A, Theriault RL, Partridge AH> ;J. Clin. Oncol.. 2011-05-20
• Ixabepilone and cyclophosphamide as neoadjuvant therapy in HER2-negative breast cancer with exploratory Oncotype DX assessments: A Sarah Cannon Research Institute phas...
  Peacock NW, Yardley DA, Hendricks CB, Huh SY, Ketchum SL, Chao C, Yoshizawa C, Shastry M, Strike B, Burris HA, Hainsworth JD> ;J. Clin. Oncol.. 2011-05-20
• 7 citations
  A Phase II Trial of Neoadjuvant Gemcitabine, Epirubicin, and Docetaxel as Primary Treatment of Patients With Locally Advanced or Inflammatory Breast Cancer
  Denise A. Yardley, N. W. Peacock, Natalie R. Dickson, Melissa B. White, Elizabeth R. Vazquez, John T. Foust, Richard Grapski, Linda K. Hendricks, William L. Scott, Joh...> ;Clinical Breast Cancer. 2010 Jun 1
• Preliminary safety results from a multicenter phase II trial of nanoparticle albumin-bound paclitaxel/cyclophosphamide in early stage breast cancer plus trastuzumab in...
  Raefsky E, Inhorn R, Lange M, Peacock N, Shastry M, Vazquez E, Priego V, Franco L, Hainsworth JD, Yardley DA> ;J. Clin. Oncol.. 2009-05-20
• Efficacy results from a multicenter phase II noncomparative two-arm pilot trial of bevacizumab with anastrozole or fulvestrant as first-line endocrine therapy for meta...
  Rubin MS, Barton J, Shipley D, Arrowsmith E, Peacock N, Hart L, Evans J, Vasquez E, Burris HA, Yardley DA> ;J. Clin. Oncol.. 2009-05-20
• A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC).
  Peacock N, Saleh M, Bendell J, Rose AA, Dong Z, Siegel PM, Crowley E, Simantov R, Vahdat L> ;J. Clin. Oncol.. 2009-05-20
• 90 citations
  Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer
  Anna Maria Storniolo, Mark D. Pegram, Beth Overmoyer, Paula Silverman, N. W. Peacock, Suzanne F. Jones, Jill Loftiss, Nikita Arya, Kevin M. Koch, Elaine M. Paul, Lini ...> ;Journal of Clinical Oncology. 2008 Jul 10
• 9 citations
  A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high...
  Denise A. Yardley, Howard A. Burris, C. Farley, J. H. Barton, N. W. Peacock, David R. Spigel, F. Anthony Greco, John D. Hainsworth> ;Clinical Breast Cancer. 2008 Jun 1
• Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC).
  Peacock NW, Infante JR, Yardley DA, Burris HA, Greco FA, Farley C, Webb C, Spigel DR, Hainsworth JD> ;J. Clin. Oncol.. 2008-05-20
• A phase II trial of biweekly pemetrexed (P) and gemcitabine (G) in the first-line treatment (tx) of patients (pts) with advanced non-small cell lung cancer (NSCLC).
  Peacock NW, Spigel DR, Hainsworth JD, Yardley DA, Burris HA, Barton JH, Patton JF, Shipley DL, Simons L, Greco FA> ;J. Clin. Oncol.. 2006-06-20
• Phase II trial of gemcitabine and carboplatin, plus trastuzumab in HER2+ patients as first line therapy in metastatic breast cancer.
  Yardley DA, Peacock NW, Shipley D, Waterhouse D, Landgdon R, Simons L, Thomas S, Hainsworth JD, Spigel DR, Burris HA> ;J. Clin. Oncol.. 2006-06-20
• Day 1 pegfilgrastim with dose dense adjuvant chemotherapy: Amelioration of docetaxel neutropenia but not that of doxorubicin/cyclophosphamide. Results from a Sarah Can...
  Yardley DA, Greco FA, Burris HA, Peacock NW, White M, Raefsky E, Thompson DS, Barton JH, Spigel DR, Hainsworth JD> ;J. Clin. Oncol.. 2005-06-01
• Phase II trial of gemcitabine plus trastuzumab in minimally pretreated HER2 overexpressing metastatic breast cancer.
  Peacock NW, Bearden J, Schnell F, White M, Greco FA, Burris HA, Barton JH, Hainsworth JD, Spigel DR, Yardley DA> ;J. Clin. Oncol.. 2005-06-01
• A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009).
  Jones SF, Hainsworth JD, Spigel DR, Peacock NW, Willcutt NT, Pandite LN, Versola MJ, Koch KM, Greco F, Burris HA> ;J. Clin. Oncol.. 2004-07-15
• Weekly bolus topotecan as secondary therapy in extensive stage small cell lung cancer: A Minnie Pearl Cancer Research Network phase II trial.
  Peacock NW, Hainsworth JD, Switzer AB, Burris HA, Barrett C, Nicolau MF, Greco FA> ;J. Clin. Oncol.. 2004-07-15
• A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon.
  Eckardt, J. R., Campbell, E., Burris, H. A., Weiss, G. R., Rodriguez, G. I., Fields, S. M., Thurman, A. M., Peacock, N. W., Cobb, P., Rothenberg, M. L.> ;Am J Clin Oncol. 1994 Dec
• Docetaxel (Taxotere) in combination: a step forward.
  Burris, H. A., Fields, S., Peacock, N.> ;Semin Oncol. 1995 Dec
• Join now to see all